Chime Biologics and Arbele Announce Strategic Collaboration at BIOHK 2025 Signing Ceremony
September 11, 2025, Hong Kong - Chime Biologics, a leading global CDMO that enables its partners' success in biologics, and Arbele, a clinical-stage biopharmaceutical company pioneering immuno-oncology and CDH17-targeted therapies, today announced the signing of a strategic collaboration agreement during BIOHK 2025.
This collaboration marks a significant step forward in advancing innovative antibody-drug conjugate (ADC) therapies. Chime Biologics and Arbele have already launched their first joint project, an IND program for a CDH17-targeted ADC, with plans to pursue a series of additional ADC projects with the same cell adhesion molecule target CDH17. These will leverage Chime Biologics’ proprietary high-throughput PCC (Preclinical Candidate) screening platform for ADCs, enabling rapid and efficient development of novel therapeutic candidates.
As part of its long-term strategy, Arbele also announced plans to expand its footprint in Biolake, Wuhan, China tapping into the region’s fast-growing biopharma R&D and manufacturing talent pools and advanced infrastructure facilities. This move will accelerate Arbele’s innovation and pipeline development in China, supporting the company’s mission to bring transformative therapies to patients worldwide. Under this framework, Arbele is actively exploring collaborations with leading local hospitals, research institutes, and companies to jointly advance innovative research and development.
Dr. John Luk, CEO of Arbele noted: “Partnering with Chime Biologics allows us to leverage their world-class CDMO capabilities and cutting-edge PCC screening platform. With our planned expansion in Biolake, Wuhan China, we are confident this collaboration will drive rapid progress across our CDH17-targeted programs and beyond.”
Dr. Jimmy Wei, President of Chime Biologics said: “Our collaboration with Arbele reflects Chime Biologics’ commitment to accelerating the development of breakthrough biologics. By combining our advanced technology platforms with Arbele’s innovative pipeline, we aim to bring life-changing ADC therapies to patients faster.”
The partnership underscores the growing momentum of cross-border innovation in biopharma, with Hong Kong and Wuhan playing critical roles in bridging global capital, talent, and technology.
About Arbele
Arbele Limited is a clinical-stage biotechnology company developing potential first-in-class and best-in-class immunotherapies for digestive tract cancers. With strategic focus on CDH17-targeted T-cell engagers and antibody-drug conjugates, we have also established IVD and CDx platforms for screening and detecting CDH17 biomarkers in blood and tissues samples to facilitate patients’ selection and prognostication. Arbele's mission is to improve survival outcomes for patients with limited treatment options. Learn more at www.arbelebio.com.
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 500 skilled employees, we share a common goal to make cutting-edge biomedicines affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. For more information, please visit www.chimebiologics.com.
